| 1 |
Cardiorenal Syndrome in Type 2 Diabetes Mellitus – Rational Use of Sodium–glucose Cotransporter-2 Inhibitors |
|
|
| Sanjay Kalra,Hasan Aydin,Manisha Sahay,Sujoy Ghosh,Sundeep Ruder,Mangesh Tiwaskar,Gary Kilov,Kamal Kishor,Tiny Nair,Vikas Makkar,Ambika Gopalakrishnan Unnikrishnan,Dinesh Dhanda,Nikhil Gupta,Bharath Srinivasan,Amit Kumar |
|
| European Endocrinology. 2020; 16(2): 113 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 2 |
Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials |
|
|
| David M. Williams,Marc Evans |
|
| Diabetes Therapy. 2020; 11(9): 1925 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 3 |
A Case of Diabetic Ketoacidosis in a Patient on an SGLT2 Inhibitor and a Ketogenic Diet: A Critical Trio Not to Be Missed |
|
|
| Samantha Steinmetz-Wood,Matthew Gilbert,Katherine Menson |
|
| Case Reports in Endocrinology. 2020; 2020: 1 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 4 |
Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight and Obese Adult Humans |
|
|
| Shane P.P. Ryan,Alissa A. Newman,Jessie R. Wilburn,Lauren D. Rhoades,S. Raj J. Trikha,Ellen C. Godwin,Hayden M. Schoenberg,Micah L. Battson,Taylor R. Ewell,Gary J. Luckasen,Laurie M. Biela,Christopher L. Melby,Christopher Bell |
|
| Nutrients. 2020; 12(2): 510 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 5 |
Metabolic Acidosis and its Predisposing Factor: Euglycemic Ketoacidosis Caused by Empagliflozin and Low-Carbohydrate Ketogenic Diet in Type 2 Diabetes Mellitus. Case Report |
|
|
| Aqsa Khan,Kamran Mushtaq,Maria Khakwani,Muhammad Shahzeb Khan Khakwani,Rizwan Mushtaq,Ross Robison,Ahsan Wahab |
|
| SN Comprehensive Clinical Medicine. 2020; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 6 |
Vasculo-metabolic Axis in Type 2 Diabetes Mellitus—Abductive Reasoning from Sodium-glucose Cotransporter 2-inhibitor Evidence |
|
|
| Jignesh Ved,Kumardeep Paul,Sanjay Kalra |
|
| US Endocrinology. 2019; 15(1): 27 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 7 |
Neuromodulatory effects of anti-diabetes medications: a mechanistic review |
|
|
| Habib Yaribeygi,Milad Ashrafizadeh,Neil C. Henney,Thozhukat Sathyapalan,Tannaz Jamialahmadi,Amirhossein Sahebkar |
|
| Pharmacological Research. 2019; : 104611 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 8 |
Metformin + Sodium-glucose Co-transporter-2 Inhibitor: Salutogenic Lifestyle Mimetics in a Tablet? |
|
|
| Sanjay Kalra,Jubbin Jacob,ManashP Baruah |
|
| Indian Journal of Endocrinology and Metabolism. 2018; 22(1): 164 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 9 |
Heart Failure With Preserved Ejection Fraction in Diabetes: Mechanisms and Management |
|
|
| Patrick Meagher,Mohamed Adam,Robert Civitarese,Antoinette Bugyei-Twum,Kim A. Connelly |
|
| Canadian Journal of Cardiology. 2018; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 10 |
Ketosis and Ketoacidosis: They May Be Sisters, but They’re Certainly Not Twins |
|
|
| Julie Stefanski |
|
| AADE in Practice. 2018; 6(6): 18 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 11 |
SGLT2-inhibitors in type-2 diabetes: The remaining questions! |
|
|
| Rajesh Rajput,Jignesh Ved |
|
| Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2017; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 12 |
Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial |
|
|
| Sanjay Kalra |
|
| Diabetes Therapy. 2016; 7(4): 601 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
